Educational corner
Is Adacolumn® effective in the treatment of Crohn’s disease? What evidence is there? How should I use it?
Adacolumn® has been used both in patients with ulcerative colitis and in patients with Crohn’s disease, as well as other rheumatological and dermatological diseases. But if we focus specifically on inflammatory bowel diseases, both in ulcerative colitis, where we have more extensive experience and there is more literature, and in Crohn’s disease, it seems to be a useful treatment with good results. It’s true that ulcerative colitis affects the mucosa. Crohn’s disease is often transmural and that might be why you have to be more patient with Crohn’s disease or have a higher number of sessions or maybe even a treatment that is a slightly longer in terms of time. Our experience in patients with Crohn’s disease of short course and who have not been very refractory to treatments with immunosuppressants or biologics is positive when this treatment is used, as I have said, at the start of the disease. Before, it would be desirable to start the immunosuppressant treatment regimens.
References:
- Adacolumn® instructions for use.
- S. Yasukawa*, F. Hirai, Y. Takada, Y. Yano Fukuoka Concomitant granulocyte and monocyte adsorption apheresis accelerates clinical efficacy and mucosal healing of colonic lesions in patients with active Crohn’s disease. U. Chikushi , Gastroenterology DPY., Chikushino, Japan.
- M. Yuksel, F. Saygili, O. Coskun, et al. : Treatment of Crohn’s disease and familial Mediterranean fever by leukopheresis: single shot for two targets.World J Gastroenterol 2015 April 7; 21(13): 4078-4081.
- K.Nagase, K.Fukunaga, S. Kashiwamura et al.: Immunoregulatory Effects of Adsorptive Granulocyte and Monocyte pheresis in Patients with Drug Refractory Crohn’s Disease , Ther Apher Dial. 2011 Aug;15(4):367-73.
- S.Kato, K.Kani, H.Takabayashi et al.: Treatment of refractory Crohn’s disease by intensive granulocyte and monocyte adsorption apheresis: a report on two drug refractory cases Intern ed. 2011;50(15):1591-3.
Contact UsFor more information
Contact Us